Nationwide, large-scale implementation of an online system for remote entry of patient-reported outcomes in rheumatology: characteristics of users and non-users and time to first entry
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Standard
Nationwide, large-scale implementation of an online system for remote entry of patient-reported outcomes in rheumatology : characteristics of users and non-users and time to first entry. / Glintborg, Bente; Jensen, Dorte Vendelbo; Terslev, Lene; Hendricks, Oliver; Østergaard, Mikkel; Rasmussen, Simon Horskjær; Jensen, Mogens Pfeiffer; Adelsten, Thomas; Colic, Ada; Danebod, Kamilla; Kildemand, Malene; Loft, Anne Gitte; Munk, Heidi Lausten; Pedersen, Jens Kristian; Østgård, René Drage; Sørensen, Christian Møller; Krogh, Niels Steen; Agerbo, Jette; Ziegler, Connie; Hetland, Merete Lund.
I: RMD Open, Bind 8, Nr. 2, e002549, 2022.Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Nationwide, large-scale implementation of an online system for remote entry of patient-reported outcomes in rheumatology
T2 - characteristics of users and non-users and time to first entry
AU - Glintborg, Bente
AU - Jensen, Dorte Vendelbo
AU - Terslev, Lene
AU - Hendricks, Oliver
AU - Østergaard, Mikkel
AU - Rasmussen, Simon Horskjær
AU - Jensen, Mogens Pfeiffer
AU - Adelsten, Thomas
AU - Colic, Ada
AU - Danebod, Kamilla
AU - Kildemand, Malene
AU - Loft, Anne Gitte
AU - Munk, Heidi Lausten
AU - Pedersen, Jens Kristian
AU - Østgård, René Drage
AU - Sørensen, Christian Møller
AU - Krogh, Niels Steen
AU - Agerbo, Jette
AU - Ziegler, Connie
AU - Hetland, Merete Lund
N1 - Publisher Copyright: ©
PY - 2022
Y1 - 2022
N2 - Aims In May 2020, a nationwide, web-based system for remote entry of patient-reported outcomes (PROs) in inflammatory rheumatic diseases was launched and implemented in routine care (DANBIO-from-home). After 1.5 years of use, we explored clinical characteristics of patients who did versus did not use the system, and the time to first entry of PROs. Methods All patients followed in DANBIO were informed about DANBIO-from-home by electronic invitations or when attending their clinic. Characteristics of patients who did/did not use DANBIO-from-home in the period after implementation were explored by multivariable logistic regression analyses including demographic and clinical variables (gender, age group, diagnosis, disease duration, use of biological disease-modifying agent (bDMARD), Health Assessment Questionnaire (HAQ), Patient Acceptable Symptom Scale (PASS)). Time from launch to first entry was presented as cumulative incidence curves by age group (<40/40-60/61-80/>80 years). Results Of 33 776 patients, 68% entered PROs using DANBIO-from-home at least once. Median (IQR) time to first entry was 27 (11-152) days. Factors associated with data entry in multivariate analyses (OR (95% CI)) were: female gender (1.19 (1.12 to 1.27)), bDMARD treatment (1.41 (1.33 to 1.50)), age 40-60 years (1.79 (1.63 to 1.97)), 61-80 years (1.87 (1.70 to 2.07), or age >80 years (0.57 (0.50 to 0.65)) (reference: age <40 years), lower HAQ (0.68 (0.65 to 0.71)) and PASS 'no' (1.09 (1.02 to 1.17). Diagnosis was not associated. Time to first entry of PROs was longest in patients <40 years of age (119 (24-184) days) and shortest in the 61-80 years age group (25 (8-139) days). Conclusion A nationwide online platform for PRO in rheumatology achieved widespread use. Higher age, male gender, conventional treatment and disability were associated with no use.
AB - Aims In May 2020, a nationwide, web-based system for remote entry of patient-reported outcomes (PROs) in inflammatory rheumatic diseases was launched and implemented in routine care (DANBIO-from-home). After 1.5 years of use, we explored clinical characteristics of patients who did versus did not use the system, and the time to first entry of PROs. Methods All patients followed in DANBIO were informed about DANBIO-from-home by electronic invitations or when attending their clinic. Characteristics of patients who did/did not use DANBIO-from-home in the period after implementation were explored by multivariable logistic regression analyses including demographic and clinical variables (gender, age group, diagnosis, disease duration, use of biological disease-modifying agent (bDMARD), Health Assessment Questionnaire (HAQ), Patient Acceptable Symptom Scale (PASS)). Time from launch to first entry was presented as cumulative incidence curves by age group (<40/40-60/61-80/>80 years). Results Of 33 776 patients, 68% entered PROs using DANBIO-from-home at least once. Median (IQR) time to first entry was 27 (11-152) days. Factors associated with data entry in multivariate analyses (OR (95% CI)) were: female gender (1.19 (1.12 to 1.27)), bDMARD treatment (1.41 (1.33 to 1.50)), age 40-60 years (1.79 (1.63 to 1.97)), 61-80 years (1.87 (1.70 to 2.07), or age >80 years (0.57 (0.50 to 0.65)) (reference: age <40 years), lower HAQ (0.68 (0.65 to 0.71)) and PASS 'no' (1.09 (1.02 to 1.17). Diagnosis was not associated. Time to first entry of PROs was longest in patients <40 years of age (119 (24-184) days) and shortest in the 61-80 years age group (25 (8-139) days). Conclusion A nationwide online platform for PRO in rheumatology achieved widespread use. Higher age, male gender, conventional treatment and disability were associated with no use.
KW - Epidemiology
KW - Health services research
KW - Patient Reported Outcome Measures
U2 - 10.1136/rmdopen-2022-002549
DO - 10.1136/rmdopen-2022-002549
M3 - Journal article
C2 - 36418086
AN - SCOPUS:85142940210
VL - 8
JO - RMD Open
JF - RMD Open
SN - 2056-5933
IS - 2
M1 - e002549
ER -
ID: 329613218